Ty Kiser
Concepts (442)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 13 | 2022 | 663 | 2.740 |
Why?
| | Venous Thromboembolism | 6 | 2025 | 313 | 2.590 |
Why?
| | Anti-Bacterial Agents | 15 | 2024 | 1798 | 2.290 |
Why?
| | Teicoplanin | 3 | 2024 | 15 | 2.250 |
Why?
| | Heparin | 10 | 2019 | 260 | 2.020 |
Why?
| | Vancomycin | 6 | 2024 | 81 | 1.930 |
Why?
| | Thrombocytopenia | 9 | 2020 | 198 | 1.880 |
Why?
| | Critical Illness | 21 | 2025 | 804 | 1.860 |
Why?
| | Hirudins | 8 | 2020 | 53 | 1.830 |
Why?
| | Factor Xa Inhibitors | 3 | 2025 | 172 | 1.790 |
Why?
| | Voriconazole | 3 | 2019 | 20 | 1.630 |
Why?
| | Peptide Fragments | 7 | 2020 | 703 | 1.540 |
Why?
| | Triazoles | 3 | 2019 | 147 | 1.500 |
Why?
| | Antithrombins | 4 | 2020 | 60 | 1.480 |
Why?
| | Peritonitis | 2 | 2024 | 84 | 1.450 |
Why?
| | Antifungal Agents | 5 | 2025 | 136 | 1.410 |
Why?
| | Peritoneal Dialysis | 2 | 2024 | 97 | 1.360 |
Why?
| | Intensive Care Units | 20 | 2025 | 800 | 1.350 |
Why?
| | Hemofiltration | 4 | 2017 | 30 | 1.310 |
Why?
| | Drug Packaging | 3 | 2016 | 45 | 1.260 |
Why?
| | Thrombin | 3 | 2020 | 152 | 1.250 |
Why?
| | Thrombosis | 4 | 2021 | 366 | 1.240 |
Why?
| | Critical Care | 11 | 2024 | 583 | 1.160 |
Why?
| | Thromboembolism | 3 | 2021 | 119 | 1.100 |
Why?
| | Pipecolic Acids | 4 | 2020 | 26 | 1.100 |
Why?
| | Fibrinolytic Agents | 4 | 2018 | 270 | 1.070 |
Why?
| | Hypnotics and Sedatives | 7 | 2025 | 198 | 1.060 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 223 | 1.050 |
Why?
| | Rivaroxaban | 3 | 2025 | 255 | 1.050 |
Why?
| | Microbial Sensitivity Tests | 6 | 2021 | 357 | 1.040 |
Why?
| | Invasive Fungal Infections | 3 | 2025 | 11 | 1.030 |
Why?
| | Pulmonary Embolism | 3 | 2019 | 225 | 1.030 |
Why?
| | Pharmacists | 5 | 2024 | 261 | 0.950 |
Why?
| | Kidney Diseases | 5 | 2021 | 407 | 0.940 |
Why?
| | beta-Cyclodextrins | 2 | 2015 | 28 | 0.940 |
Why?
| | Middle Aged | 53 | 2025 | 33228 | 0.930 |
Why?
| | Hospitalization | 8 | 2025 | 2183 | 0.910 |
Why?
| | Pharmacy Service, Hospital | 2 | 2024 | 90 | 0.860 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2019 | 1036 | 0.860 |
Why?
| | Syringes | 3 | 2016 | 44 | 0.840 |
Why?
| | Retrospective Studies | 36 | 2025 | 15504 | 0.830 |
Why?
| | Aged | 38 | 2025 | 23794 | 0.830 |
Why?
| | Renal Replacement Therapy | 4 | 2022 | 92 | 0.820 |
Why?
| | Professional Role | 1 | 2024 | 165 | 0.810 |
Why?
| | Humans | 97 | 2025 | 136764 | 0.800 |
Why?
| | Factor Xa | 2 | 2021 | 32 | 0.780 |
Why?
| | Dalteparin | 2 | 2020 | 10 | 0.770 |
Why?
| | Drug Stability | 4 | 2016 | 167 | 0.750 |
Why?
| | Hospital Mortality | 6 | 2025 | 901 | 0.740 |
Why?
| | Drug Monitoring | 4 | 2017 | 218 | 0.730 |
Why?
| | Nephrologists | 1 | 2021 | 13 | 0.730 |
Why?
| | Partial Thromboplastin Time | 5 | 2014 | 57 | 0.720 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2020 | 70 | 0.720 |
Why?
| | Recombinant Proteins | 10 | 2021 | 1350 | 0.720 |
Why?
| | Adult | 40 | 2025 | 37630 | 0.710 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 556 | 0.690 |
Why?
| | Blood Coagulation Tests | 3 | 2016 | 67 | 0.680 |
Why?
| | Male | 56 | 2025 | 67309 | 0.680 |
Why?
| | Atrial Fibrillation | 2 | 2022 | 388 | 0.680 |
Why?
| | Female | 56 | 2025 | 72787 | 0.680 |
Why?
| | Gram-Positive Bacteria | 1 | 2020 | 48 | 0.650 |
Why?
| | Dose-Response Relationship, Drug | 11 | 2019 | 2052 | 0.650 |
Why?
| | Kidney Failure, Chronic | 3 | 2020 | 566 | 0.640 |
Why?
| | Pseudomonas Infections | 2 | 2013 | 225 | 0.640 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 2 | 2023 | 20 | 0.630 |
Why?
| | Antiviral Agents | 3 | 2020 | 739 | 0.620 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 188 | 0.610 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 33 | 0.600 |
Why?
| | Macrolides | 1 | 2019 | 63 | 0.600 |
Why?
| | Diabetic Ketoacidosis | 1 | 2021 | 200 | 0.590 |
Why?
| | Obesity, Morbid | 1 | 2022 | 259 | 0.580 |
Why?
| | Dexmedetomidine | 4 | 2014 | 43 | 0.580 |
Why?
| | Cold Temperature | 2 | 2016 | 177 | 0.580 |
Why?
| | Nitriles | 1 | 2019 | 172 | 0.570 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 79 | 0.570 |
Why?
| | Blood Transfusion | 2 | 2020 | 323 | 0.560 |
Why?
| | Hemorrhage | 6 | 2022 | 721 | 0.560 |
Why?
| | Hepatorenal Syndrome | 2 | 2009 | 16 | 0.560 |
Why?
| | Anticonvulsants | 2 | 2017 | 215 | 0.560 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 745 | 0.550 |
Why?
| | Aged, 80 and over | 14 | 2025 | 7585 | 0.540 |
Why?
| | Piracetam | 1 | 2017 | 13 | 0.540 |
Why?
| | Treatment Outcome | 20 | 2025 | 10744 | 0.540 |
Why?
| | Ribavirin | 2 | 2020 | 91 | 0.530 |
Why?
| | Lung Transplantation | 3 | 2020 | 313 | 0.520 |
Why?
| | Glass | 1 | 2016 | 45 | 0.520 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 85 | 0.520 |
Why?
| | Thiocyanates | 1 | 2016 | 31 | 0.510 |
Why?
| | Nitroprusside | 1 | 2016 | 69 | 0.510 |
Why?
| | Thiosulfates | 1 | 2016 | 19 | 0.510 |
Why?
| | Freezing | 1 | 2016 | 90 | 0.500 |
Why?
| | Cyclodextrins | 1 | 2015 | 7 | 0.490 |
Why?
| | Infusions, Intravenous | 6 | 2020 | 412 | 0.480 |
Why?
| | Neoplasms | 3 | 2020 | 2644 | 0.470 |
Why?
| | Cerebral Hemorrhage | 1 | 2016 | 108 | 0.470 |
Why?
| | Pyridines | 1 | 2019 | 506 | 0.470 |
Why?
| | Curriculum | 2 | 2021 | 976 | 0.470 |
Why?
| | Therapeutics | 1 | 2015 | 14 | 0.470 |
Why?
| | Vasodilator Agents | 2 | 2016 | 331 | 0.460 |
Why?
| | Cardiopulmonary Bypass | 2 | 2016 | 209 | 0.460 |
Why?
| | Respiratory Insufficiency | 4 | 2024 | 317 | 0.450 |
Why?
| | Antidotes | 1 | 2016 | 143 | 0.450 |
Why?
| | Stroke | 2 | 2022 | 1118 | 0.440 |
Why?
| | Kidney | 2 | 2021 | 1467 | 0.430 |
Why?
| | Vasoconstriction | 2 | 2023 | 202 | 0.430 |
Why?
| | Osmotic Pressure | 1 | 2014 | 37 | 0.430 |
Why?
| | Methylprednisolone | 1 | 2014 | 85 | 0.430 |
Why?
| | Dronabinol | 1 | 2016 | 226 | 0.420 |
Why?
| | Cohort Studies | 14 | 2021 | 5701 | 0.420 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1507 | 0.380 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 116 | 0.380 |
Why?
| | Ganciclovir | 1 | 2012 | 53 | 0.380 |
Why?
| | Arginine | 4 | 2020 | 271 | 0.370 |
Why?
| | Benzodiazepines | 3 | 2025 | 153 | 0.370 |
Why?
| | Administration, Oral | 4 | 2022 | 813 | 0.370 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 443 | 0.370 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 51 | 0.370 |
Why?
| | Prospective Studies | 9 | 2025 | 7572 | 0.360 |
Why?
| | Pseudomonas aeruginosa | 2 | 2013 | 352 | 0.360 |
Why?
| | Pharmacies | 2 | 2021 | 38 | 0.350 |
Why?
| | Pharmacy | 2 | 2021 | 32 | 0.350 |
Why?
| | Substance Withdrawal Syndrome | 3 | 2022 | 178 | 0.350 |
Why?
| | Empirical Research | 1 | 2011 | 21 | 0.350 |
Why?
| | Drug Resistance, Multiple | 1 | 2010 | 25 | 0.340 |
Why?
| | Nomograms | 1 | 2011 | 54 | 0.340 |
Why?
| | Acute Kidney Injury | 4 | 2018 | 809 | 0.330 |
Why?
| | Academic Medical Centers | 3 | 2019 | 504 | 0.330 |
Why?
| | Cytomegalovirus Infections | 1 | 2012 | 192 | 0.330 |
Why?
| | Midazolam | 2 | 2024 | 56 | 0.320 |
Why?
| | Neurosurgical Procedures | 2 | 2024 | 197 | 0.320 |
Why?
| | Neuromuscular Blockade | 2 | 2025 | 31 | 0.320 |
Why?
| | Sulfonamides | 4 | 2020 | 513 | 0.320 |
Why?
| | Time Factors | 7 | 2018 | 6806 | 0.310 |
Why?
| | Drug Therapy, Combination | 5 | 2021 | 1062 | 0.300 |
Why?
| | Young Adult | 9 | 2025 | 13129 | 0.290 |
Why?
| | Propofol | 2 | 2025 | 73 | 0.290 |
Why?
| | Students, Pharmacy | 2 | 2021 | 97 | 0.290 |
Why?
| | Burns | 2 | 2018 | 325 | 0.290 |
Why?
| | Thrombin Time | 2 | 2020 | 12 | 0.280 |
Why?
| | Daptomycin | 2 | 2021 | 18 | 0.280 |
Why?
| | Polypropylenes | 1 | 2007 | 13 | 0.270 |
Why?
| | Sympathomimetics | 1 | 2007 | 21 | 0.270 |
Why?
| | Expectorants | 1 | 2007 | 24 | 0.270 |
Why?
| | Phenylephrine | 1 | 2007 | 75 | 0.270 |
Why?
| | Administration, Intravenous | 3 | 2017 | 155 | 0.270 |
Why?
| | Patient Discharge | 3 | 2018 | 894 | 0.270 |
Why?
| | Pharmacoepidemiology | 2 | 2019 | 19 | 0.260 |
Why?
| | Drug Storage | 3 | 2016 | 57 | 0.260 |
Why?
| | Shock, Septic | 2 | 2022 | 219 | 0.260 |
Why?
| | Drug Compounding | 2 | 2017 | 101 | 0.260 |
Why?
| | Lorazepam | 3 | 2014 | 27 | 0.260 |
Why?
| | Ofloxacin | 1 | 2006 | 24 | 0.250 |
Why?
| | Levofloxacin | 1 | 2006 | 27 | 0.250 |
Why?
| | Acetylcysteine | 1 | 2007 | 145 | 0.250 |
Why?
| | Anesthetics | 1 | 2007 | 81 | 0.250 |
Why?
| | Respiration | 1 | 2007 | 199 | 0.250 |
Why?
| | Adolescent | 10 | 2025 | 21382 | 0.240 |
Why?
| | Alcoholism | 2 | 2023 | 804 | 0.240 |
Why?
| | Gentamicins | 2 | 2023 | 54 | 0.240 |
Why?
| | Models, Biological | 1 | 2013 | 1773 | 0.240 |
Why?
| | Area Under Curve | 4 | 2019 | 314 | 0.240 |
Why?
| | Arginine Vasopressin | 1 | 2005 | 44 | 0.240 |
Why?
| | Octreotide | 1 | 2005 | 26 | 0.240 |
Why?
| | Vasoconstrictor Agents | 2 | 2023 | 139 | 0.240 |
Why?
| | Pneumonia | 3 | 2023 | 635 | 0.240 |
Why?
| | Neuromuscular Blocking Agents | 2 | 2018 | 25 | 0.230 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2021 | 3710 | 0.220 |
Why?
| | Warfarin | 2 | 2022 | 153 | 0.220 |
Why?
| | Cross-Over Studies | 2 | 2020 | 562 | 0.220 |
Why?
| | Length of Stay | 4 | 2019 | 1205 | 0.220 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2024 | 597 | 0.210 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2016 | 560 | 0.210 |
Why?
| | Temperature | 3 | 2016 | 675 | 0.210 |
Why?
| | Blood Coagulation | 2 | 2016 | 255 | 0.200 |
Why?
| | Saline Solution, Hypertonic | 1 | 2023 | 41 | 0.200 |
Why?
| | Liver Diseases | 1 | 2006 | 311 | 0.200 |
Why?
| | Ethanol | 3 | 2022 | 606 | 0.190 |
Why?
| | Incidence | 2 | 2020 | 2792 | 0.190 |
Why?
| | Risk Factors | 7 | 2023 | 10326 | 0.190 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1301 | 0.190 |
Why?
| | Thinness | 1 | 2022 | 91 | 0.180 |
Why?
| | Liver Transplantation | 1 | 2009 | 871 | 0.180 |
Why?
| | Sexual Harassment | 1 | 2021 | 27 | 0.180 |
Why?
| | Aspergillosis | 1 | 2021 | 21 | 0.180 |
Why?
| | Prothrombin | 1 | 2021 | 26 | 0.180 |
Why?
| | Statistics, Nonparametric | 3 | 2017 | 431 | 0.180 |
Why?
| | Candidiasis | 1 | 2021 | 56 | 0.180 |
Why?
| | Pharmaceutical Services | 1 | 2021 | 83 | 0.170 |
Why?
| | Community Pharmacy Services | 1 | 2021 | 45 | 0.170 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 785 | 0.170 |
Why?
| | Cephalosporins | 1 | 2021 | 48 | 0.170 |
Why?
| | Ascitic Fluid | 1 | 2020 | 15 | 0.170 |
Why?
| | Vasoplegia | 1 | 2020 | 2 | 0.170 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 992 | 0.170 |
Why?
| | Salvage Therapy | 1 | 2021 | 142 | 0.160 |
Why?
| | Platelet Count | 1 | 2020 | 85 | 0.160 |
Why?
| | Monte Carlo Method | 2 | 2013 | 147 | 0.160 |
Why?
| | Hydroxocobalamin | 1 | 2020 | 26 | 0.160 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 254 | 0.150 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 291 | 0.150 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2020 | 127 | 0.150 |
Why?
| | Body Weight | 2 | 2021 | 985 | 0.150 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 532 | 0.150 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 6 | 0.150 |
Why?
| | Hemostasis | 1 | 2019 | 82 | 0.150 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 257 | 0.150 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.150 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 21 | 0.140 |
Why?
| | Coronary Circulation | 1 | 2018 | 140 | 0.140 |
Why?
| | Gastric Emptying | 2 | 2008 | 38 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 25 | 0.140 |
Why?
| | Asthma | 2 | 2022 | 2282 | 0.140 |
Why?
| | Calcineurin Inhibitors | 1 | 2018 | 72 | 0.140 |
Why?
| | Cardiologists | 1 | 2018 | 45 | 0.140 |
Why?
| | Logistic Models | 3 | 2017 | 2067 | 0.140 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 234 | 0.140 |
Why?
| | Kidney Transplantation | 2 | 2018 | 701 | 0.140 |
Why?
| | United States | 8 | 2025 | 14691 | 0.140 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 150 | 0.140 |
Why?
| | Gastrointestinal Agents | 2 | 2008 | 65 | 0.140 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2017 | 17 | 0.140 |
Why?
| | Antibodies, Bacterial | 1 | 2018 | 146 | 0.140 |
Why?
| | Occupational Therapy | 1 | 2019 | 100 | 0.140 |
Why?
| | Polyneuropathies | 1 | 2017 | 55 | 0.140 |
Why?
| | Immunity, Humoral | 1 | 2018 | 116 | 0.140 |
Why?
| | Self-Directed Learning as Topic | 1 | 2017 | 4 | 0.130 |
Why?
| | Pharmaceutical Solutions | 1 | 2016 | 14 | 0.130 |
Why?
| | Pneumococcal Vaccines | 1 | 2018 | 142 | 0.130 |
Why?
| | Disease-Free Survival | 1 | 2018 | 685 | 0.130 |
Why?
| | Career Mobility | 1 | 2017 | 68 | 0.130 |
Why?
| | Chromatography, Reverse-Phase | 1 | 2016 | 28 | 0.130 |
Why?
| | Propensity Score | 2 | 2017 | 289 | 0.130 |
Why?
| | Capsules | 1 | 2016 | 38 | 0.130 |
Why?
| | Immunotherapy | 1 | 2021 | 640 | 0.130 |
Why?
| | Transplant Recipients | 2 | 2018 | 179 | 0.130 |
Why?
| | Patient Readmission | 2 | 2019 | 694 | 0.130 |
Why?
| | Databases, Factual | 2 | 2019 | 1351 | 0.130 |
Why?
| | Solubility | 1 | 2016 | 245 | 0.130 |
Why?
| | Staphylococcal Infections | 1 | 2021 | 399 | 0.130 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 308 | 0.120 |
Why?
| | Psychotropic Drugs | 1 | 2016 | 68 | 0.120 |
Why?
| | Cholestyramine Resin | 1 | 2015 | 7 | 0.120 |
Why?
| | Drug Prescriptions | 1 | 2018 | 243 | 0.120 |
Why?
| | Enteral Nutrition | 2 | 2008 | 201 | 0.120 |
Why?
| | Regression Analysis | 2 | 2016 | 1022 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 801 | 0.120 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2019 | 253 | 0.120 |
Why?
| | Calibration | 1 | 2016 | 146 | 0.120 |
Why?
| | Respiration, Artificial | 4 | 2025 | 642 | 0.120 |
Why?
| | Pharmacokinetics | 1 | 2015 | 29 | 0.120 |
Why?
| | Isoxazoles | 1 | 2015 | 54 | 0.120 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 509 | 0.120 |
Why?
| | Societies, Pharmaceutical | 1 | 2015 | 21 | 0.120 |
Why?
| | Internship, Nonmedical | 1 | 2015 | 14 | 0.120 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 350 | 0.120 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 533 | 0.120 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2014 | 29 | 0.110 |
Why?
| | Administration, Inhalation | 1 | 2016 | 683 | 0.110 |
Why?
| | Anti-Ulcer Agents | 1 | 2014 | 16 | 0.110 |
Why?
| | Histamine H2 Antagonists | 1 | 2014 | 30 | 0.110 |
Why?
| | Teaching | 1 | 2017 | 224 | 0.110 |
Why?
| | Double-Blind Method | 4 | 2014 | 1981 | 0.110 |
Why?
| | Prosthesis-Related Infections | 1 | 2015 | 95 | 0.110 |
Why?
| | Peptic Ulcer | 1 | 2014 | 20 | 0.110 |
Why?
| | beta-Alanine | 1 | 2014 | 16 | 0.110 |
Why?
| | Diltiazem | 1 | 2014 | 29 | 0.110 |
Why?
| | Dabigatran | 1 | 2014 | 22 | 0.110 |
Why?
| | Pyridones | 1 | 2016 | 168 | 0.110 |
Why?
| | Thromboplastin | 1 | 2014 | 74 | 0.110 |
Why?
| | Drug Dosage Calculations | 1 | 2014 | 23 | 0.110 |
Why?
| | Medication Adherence | 1 | 2018 | 466 | 0.110 |
Why?
| | Immunoglobulin G | 1 | 2018 | 887 | 0.110 |
Why?
| | Proton Pump Inhibitors | 1 | 2014 | 109 | 0.110 |
Why?
| | Seizures | 1 | 2017 | 425 | 0.100 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2014 | 132 | 0.100 |
Why?
| | Guidelines as Topic | 1 | 2015 | 275 | 0.100 |
Why?
| | Benzimidazoles | 1 | 2014 | 170 | 0.100 |
Why?
| | Oxazolidinones | 1 | 2012 | 15 | 0.100 |
Why?
| | Antirheumatic Agents | 1 | 2015 | 292 | 0.100 |
Why?
| | Learning | 1 | 2017 | 406 | 0.100 |
Why?
| | Conscious Sedation | 1 | 2013 | 91 | 0.100 |
Why?
| | Antibiotic Prophylaxis | 1 | 2014 | 115 | 0.100 |
Why?
| | APACHE | 2 | 2010 | 69 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 805 | 0.100 |
Why?
| | Community-Acquired Infections | 1 | 2014 | 169 | 0.100 |
Why?
| | Acetamides | 1 | 2012 | 36 | 0.100 |
Why?
| | Pyrazoles | 1 | 2016 | 423 | 0.100 |
Why?
| | Sirolimus | 1 | 2014 | 275 | 0.100 |
Why?
| | Motivation | 1 | 2017 | 567 | 0.100 |
Why?
| | Treatment Failure | 1 | 2013 | 354 | 0.090 |
Why?
| | Patient Selection | 1 | 2016 | 690 | 0.090 |
Why?
| | Colorado | 3 | 2017 | 4518 | 0.090 |
Why?
| | Mental Recall | 1 | 2013 | 200 | 0.090 |
Why?
| | Coronary Artery Bypass | 1 | 2014 | 233 | 0.090 |
Why?
| | Acute Disease | 1 | 2015 | 1004 | 0.090 |
Why?
| | Metabolic Clearance Rate | 1 | 2012 | 115 | 0.090 |
Why?
| | Metoclopramide | 2 | 2008 | 19 | 0.090 |
Why?
| | Erythromycin | 2 | 2008 | 25 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2012 | 206 | 0.090 |
Why?
| | Research | 1 | 2015 | 448 | 0.090 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2014 | 180 | 0.090 |
Why?
| | Lipids | 1 | 2016 | 665 | 0.090 |
Why?
| | Fellowships and Scholarships | 1 | 2015 | 303 | 0.090 |
Why?
| | Disease Progression | 2 | 2020 | 2750 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2014 | 659 | 0.090 |
Why?
| | Aortic Valve | 1 | 2014 | 351 | 0.090 |
Why?
| | Imipenem | 1 | 2010 | 18 | 0.080 |
Why?
| | Genes, Regulator | 1 | 2010 | 37 | 0.080 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 305 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2015 | 593 | 0.080 |
Why?
| | Drug Resistance | 1 | 2011 | 169 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 496 | 0.080 |
Why?
| | Hypothermia, Induced | 1 | 2011 | 79 | 0.080 |
Why?
| | Pharmaceutical Vehicles | 1 | 2009 | 12 | 0.080 |
Why?
| | Propylene Glycol | 1 | 2009 | 10 | 0.080 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 345 | 0.080 |
Why?
| | Protein C | 1 | 2010 | 59 | 0.080 |
Why?
| | Risk Assessment | 2 | 2016 | 3432 | 0.080 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 44 | 0.080 |
Why?
| | Biomedical Research | 1 | 2015 | 688 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2010 | 267 | 0.070 |
Why?
| | Aging | 1 | 2019 | 1861 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1935 | 0.070 |
Why?
| | Acetaminophen | 2 | 2008 | 266 | 0.070 |
Why?
| | Certification | 1 | 2009 | 103 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2008 | 159 | 0.070 |
Why?
| | Standard of Care | 2 | 2021 | 72 | 0.070 |
Why?
| | Biomarkers | 2 | 2016 | 4143 | 0.070 |
Why?
| | Lung Diseases | 1 | 2014 | 767 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2019 | 6033 | 0.070 |
Why?
| | Cost Control | 1 | 2007 | 39 | 0.070 |
Why?
| | Databases as Topic | 1 | 2007 | 67 | 0.070 |
Why?
| | Liver Cirrhosis | 1 | 2009 | 316 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2010 | 435 | 0.060 |
Why?
| | Creatinine | 1 | 2008 | 499 | 0.060 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2008 | 124 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 2046 | 0.060 |
Why?
| | Half-Life | 1 | 2006 | 164 | 0.060 |
Why?
| | Fentanyl | 1 | 2007 | 94 | 0.060 |
Why?
| | Schools, Pharmacy | 2 | 2017 | 47 | 0.060 |
Why?
| | Antidiuretic Agents | 1 | 2005 | 6 | 0.060 |
Why?
| | Platelet Aggregation | 1 | 2005 | 100 | 0.060 |
Why?
| | Platelet Activation | 1 | 2005 | 93 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2822 | 0.060 |
Why?
| | Chromatography, Liquid | 1 | 2007 | 433 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 2605 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 1571 | 0.050 |
Why?
| | DNA | 1 | 2010 | 1458 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 94 | 0.050 |
Why?
| | Penicillins | 1 | 2023 | 58 | 0.050 |
Why?
| | Animals | 2 | 2016 | 36823 | 0.050 |
Why?
| | Transcription Factors | 1 | 2010 | 1718 | 0.050 |
Why?
| | Minnesota | 1 | 2022 | 162 | 0.050 |
Why?
| | Vasopressins | 1 | 2022 | 64 | 0.050 |
Why?
| | Computer Simulation | 1 | 2006 | 973 | 0.050 |
Why?
| | Norepinephrine | 1 | 2022 | 204 | 0.040 |
Why?
| | Serum Albumin | 1 | 2022 | 150 | 0.040 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 12 | 0.040 |
Why?
| | Status Asthmaticus | 1 | 2020 | 11 | 0.040 |
Why?
| | Gender Identity | 1 | 2021 | 124 | 0.040 |
Why?
| | Polyphosphates | 1 | 2020 | 37 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 250 | 0.040 |
Why?
| | Rifampin | 1 | 2021 | 84 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1905 | 0.040 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 5742 | 0.040 |
Why?
| | Methylene Blue | 1 | 2020 | 23 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 382 | 0.040 |
Why?
| | Hypersensitivity | 1 | 2023 | 257 | 0.040 |
Why?
| | Sepsis | 2 | 2020 | 614 | 0.040 |
Why?
| | Pilot Projects | 2 | 2015 | 1692 | 0.040 |
Why?
| | Mutation | 1 | 2010 | 3946 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2021 | 281 | 0.040 |
Why?
| | Vascular Resistance | 1 | 2020 | 372 | 0.040 |
Why?
| | Bacteremia | 1 | 2021 | 213 | 0.040 |
Why?
| | Sex Factors | 2 | 2018 | 2060 | 0.040 |
Why?
| | Hospitals, Rural | 1 | 2018 | 39 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2022 | 656 | 0.040 |
Why?
| | Hospital Charges | 1 | 2017 | 44 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2020 | 652 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 133 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2019 | 404 | 0.030 |
Why?
| | Muscular Diseases | 1 | 2017 | 114 | 0.030 |
Why?
| | Drug Interactions | 1 | 2018 | 407 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 190 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2018 | 229 | 0.030 |
Why?
| | Problem-Based Learning | 1 | 2017 | 91 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1614 | 0.030 |
Why?
| | Pharmacology, Clinical | 1 | 2015 | 9 | 0.030 |
Why?
| | Risk | 1 | 2018 | 908 | 0.030 |
Why?
| | Education, Pharmacy | 1 | 2017 | 120 | 0.030 |
Why?
| | Expert Testimony | 1 | 2015 | 39 | 0.030 |
Why?
| | Peptic Ulcer Hemorrhage | 1 | 2014 | 6 | 0.030 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2014 | 15 | 0.030 |
Why?
| | Checklist | 1 | 2015 | 93 | 0.030 |
Why?
| | Bradycardia | 1 | 2014 | 55 | 0.030 |
Why?
| | Educational Measurement | 1 | 2017 | 281 | 0.030 |
Why?
| | Infusions, Parenteral | 1 | 2014 | 40 | 0.030 |
Why?
| | Receptors, Steroid | 1 | 2014 | 50 | 0.030 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 48 | 0.030 |
Why?
| | Stress Disorders, Traumatic, Acute | 1 | 2013 | 8 | 0.030 |
Why?
| | Everolimus | 1 | 2014 | 91 | 0.030 |
Why?
| | Delphi Technique | 1 | 2015 | 273 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2014 | 88 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2014 | 330 | 0.030 |
Why?
| | Hypotension | 1 | 2014 | 122 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2014 | 387 | 0.030 |
Why?
| | Demography | 1 | 2014 | 291 | 0.030 |
Why?
| | Cerebral Ventriculitis | 1 | 2012 | 4 | 0.030 |
Why?
| | Injections, Intraventricular | 1 | 2012 | 55 | 0.030 |
Why?
| | Vancomycin Resistance | 1 | 2012 | 16 | 0.030 |
Why?
| | Linezolid | 1 | 2012 | 20 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 5423 | 0.020 |
Why?
| | Enterococcus faecium | 1 | 2012 | 20 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 562 | 0.020 |
Why?
| | Drainage | 1 | 2012 | 171 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 649 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2014 | 441 | 0.020 |
Why?
| | Contraindications | 1 | 2010 | 90 | 0.020 |
Why?
| | Governing Board | 1 | 2009 | 7 | 0.020 |
Why?
| | Multiple Organ Failure | 1 | 2010 | 127 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 2878 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 889 | 0.020 |
Why?
| | Observer Variation | 1 | 2010 | 341 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1914 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 2010 | 170 | 0.020 |
Why?
| | Dopamine Antagonists | 1 | 2008 | 27 | 0.020 |
Why?
| | Specialization | 1 | 2009 | 143 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 363 | 0.020 |
Why?
| | Intubation, Gastrointestinal | 1 | 2008 | 78 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1044 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2014 | 3540 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 1163 | 0.020 |
Why?
| | Anxiety | 1 | 2013 | 1031 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 4013 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2014 | 5106 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2022 | 0.010 |
Why?
| | Depression | 1 | 2013 | 1395 | 0.010 |
Why?
| | Age Factors | 1 | 2009 | 3284 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3264 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 1094 | 0.010 |
Why?
| | Physicians | 1 | 2010 | 907 | 0.010 |
Why?
|
|
Kiser's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|